In conclusion, the results of current meta- and bioinformatics analyses showed that overexpression of SNHG12 was significantly related to unfavorable survival outcome and aggressive clinical characteristics including LNM, distant metastasis, high clinical stage, large tumor size, and poor tumor differentiation in multiple cancers, which suggested that SNHG12 might act as a promising diagnostic or prognostic biomarker in cancer patients. Here, SNHG12 is linked to cancer.